FDA approves dupilumab efficacy supplement for allergic fungal rhinosinusitis with AIMS trial basis

FDA approved a priority efficacy supplement for dupilumab in allergic fungal rhinosinusitis on 23 February 2026, with the AIMS randomized trial and label-embedded endpoint evidence supporting the decision context.